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Background: LKB1 regulates multiple aspects of pancreatic  cell biology.
Results: LKB1 loss in  cells leads to profound mitochondrial defects yet increases glucose-stimulated insulin secretion in a
mitochondria-independent mechanism.
Conclusion: LKB1 is essential for mitochondrial maintenance and negatively regulates a distal step of insulin secretion.
Significance: LKB1 loss exposes powerful mechanisms of insulin secretion that can override defects in the classic triggering
pathway.
The tumor suppressor liver kinase B1 (LKB1) is an important
regulator of pancreatic  cell biology. LKB1-dependent phos-
phorylation of distinct AMPK (adenosinemonophosphate-acti-
vated protein kinase) family members determines proper  cell
polarity and restricts  cell size, total  cell mass, and glucose-
stimulated insulin secretion (GSIS). However, the full spectrum
of LKB1 effects and the mechanisms involved in the secretory
phenotype remain incompletely understood. We report here
that in the absence of LKB1 in  cells, GSIS is dramatically and
persistently improved. The enhancement is seen both in vivo
and in vitro and cannot be explained by altered cell polarity,
increased cell number, or increased insulin content. Increased
secretion does require membrane depolarization and calcium
influx but appears to rely mostly on a distal step in the secretion
pathway. Surprisingly, enhanced GSIS is seen despite profound
defects in mitochondrial structure and function in LKB1-defi-
cient  cells, expected to greatly diminish insulin secretion via
the classic triggering pathway. Thus LKB1 is essential for mito-
chondrial homeostasis in  cells and in parallel is a powerful
negative regulator of insulin secretion. This study shows that 
cells can be manipulated to enhance GSIS to supra-normal lev-
els even in the face of defective mitochondria and without dete-
rioration over months.
A large body of evidence has positioned LKB16 as an evolu-
tionarily conserved, central regulator of diverse cellular pro-
cesses. LKB1 is essential for the determination and mainte-
nance of proper cell polarity (1–3), for genome integrity and
cytokinesis (4–6), and for linking cellular energy charge to cel-
lular metabolism (7). All functions of LKB1 are believed to be
mediated via phosphorylation and activation of a well defined
set of 12 kinases from the AMPK family (8, 9). For example,
phosphorylation of AMPK restricts mTOR signaling (via phos-
phorylation of TSC1/2) and lipid biosynthesis (via phosphory-
lation of acetyl-CoA carboxylase) (10–13), whereas phosphor-
ylation of BRSK1/2 and MARK1–4 regulates the cytoskeleton,
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thereby determining cell polarity (14–16). At the tissue level,
LKB1 functions as a powerful tumor suppressor gene (17–19)
that is also essential for the maintenance of stem cells in a qui-
escent state (20–22).
In the context of pancreatic  cells, we (23, 24) and others
(25) previously showed that LKB1 has multiple structural and
functional roles. Deletion of LKB1 in adult  cells led to cellular
hypertrophy (due to increased mTORC1 activity, secondary to
inactivation of AMPK), increased  cell proliferation, dramatic
alteration of cell polarity (due to inactivation ofMARK2), and
increased glucose-stimulated insulin secretion, leading to
accelerated clearance of glucose in vivo and to protection
against high fat diet-induced glucose intolerance. The mecha-
nisms underlying the enhancement of insulin secretion in
LKB1-deficient  cells have remained ill-defined. It was pro-
posed that altered polarity of cells may enhance insulin secre-
tion to nearby blood vessels (23) or alternatively that enhanced
insulin secretion resulted from increased insulin content in 
cells or increased overall  cell mass in LKB1 mutants (24, 25).
Recently, two direct phosphorylation targets of LKB1 were
reported to act as positive regulators of glucose-stimulated
insulin secretion. SIK2 was shown to enhance insulin secretion
via phosphorylation and degradation of CDK5R1/p35 (26), and
SAD-A was implicated as a regulator of  cell size and GSIS
(27). Deletion of either gene disrupted insulin secretion.
Because LKB1 deficiency is expected to functionally inactivate
both SIK2 and SAD-A, a powerful mechanism must be acti-
vated upon LKB1 deletion that can compensate for these losses
and lead to a net enhancement of insulin secretion.
Here we have examined the mechanisms accounting for
enhanced insulin secretion in LKB1-deficient  cells. We dem-
onstrate that enhanced secretion upon LKB1 inactivation
requires the classical triggering pathway but acts primarily at a
more distal step. Surprisingly, we found that LKB1 deficiency
causes a dramatic deterioration of mitochondrial structure and
function. However the amplification of insulin secretion by
LKB1 deficiency overrides this defect, exposing a hitherto
unrecognized mechanism for long term enhancement of  cell
function.
Experimental Procedures
Mice—Strains used in this study were LKB1lox/lox (2) crossed
with either pdx1-CreERTM (28), insulin-CreERTM (29), or Ins1-
Cre (30). These configurations resulted in essentially identical
in vivo glucose homeostasis phenotypes (not shown and seeRef.
30). We encountered difficulties in islet isolation from Pdx1-
CreER;LKB1lox/loxmice after tamoxifen injection, probably due
to acinar deletion of LKB1 that affected the islet mantle. There-
fore, in vitro experiments were performed on islets isolated
from Insulin-CreER;LKB1lox/lox mice or Ins-Cre;LKB1lox/lox
mice. For convenience, LKB1-deficient mice are labeled in the
manuscript as LKB mice. Controls were lox/lox littermates.
Tamoxifen (Sigma, 20 mg/ml in corn oil) was injected sub-
cutaneously to adult mice (1–2months old). Two daily doses of
8mgwere used to achieve near total deletion of LKB1 in cells,
and animals were studied 2–16 months later. Because recom-
bination occurred in utero in Ins1-Cre;LKB1lox/lox mice (30),
these animals were used at younger ages (8–12 weeks) as indi-
cated in Fig. 4. Glyburide and Nifedipine were injected intra-
peritoneally at the indicated doses.Measurements of blood glu-
cose and serum insulin were performed as described elsewhere
(31). The joint ethics committee (Institutional Animal Care and
Use Committees) of the Hebrew University and Hadassah
Medical Center and the United Kingdom Home Office (PPL
70/06608) approved the study protocol for animal welfare. The
Hebrew University is an AAALAC International-accredited
institute.
Pancreatic Insulin Content and  Cell Mass—The pancreas
was homogenized in acid ethanol (0.18 M HCl in 70% ethanol).
After overnight incubation at 4 °C, homogenate was diluted
1:10 with 0.1% BSA in PBS. Insulin content wasmeasured using
the ELISA kit (Crystal Chem) and was calculated per pancreas
weight.
For  cell mass calculation, consecutive paraffin sections 75
m apart spanning the entire pancreas (10 sections/pan-
creas) were stained for insulin and hematoxylin. Digital images
of sections at a magnification of 40 were obtained and
stitched usingNIS-Elements software, and the fraction of tissue
covered by insulin staining was determined.  cell mass was
calculated as the product of pancreas weight and the fraction of
tissue covered by  cells.
Isolation and Culture of Islets of Langerhans—Islets were iso-
lated using collagenase P (Roche Applied Science) injected to
the pancreatic duct followed by Histopaque (1119 and 1077,
Sigma) gradient. Insulin secretion experimentswere performed
after an overnight incubation in RPMI 1640 supplementedwith
10% fetal bovine serum, L-glutamine, and penicillin/streptomy-
cin unless stated otherwise.
Adenoviral Infection of Islets—Islets were infected with an
adenovirus encoding human LKB1 (Ad-STK11, Vector Biolabs,
Philadelphia, PA). Infection was performed at the multiplicity
of infection indicated in RPMI 1640 treated with 100 units/ml
penicillin and streptomycin and 10% (v/v) heat-inactivated fetal
bovine serum (FBS) for 48 h before measurements.
Static andDynamic Stimulation of Insulin Secretion—Insulin
secretion studies were performed in Krebs-Ringer buffer
(KRBB) containing 114.4 mmol/liter NaCl, 5 mmol/liter KCl,
24 mmol/liter NaHCO3, 1 mmol/liter MgCl2, 2.2 mmol/liter
CaCl2, 10 mmol/liter HEPES, and 0.5% BSA, adjusted to pH
7.35. In static incubation experiments, 25–30 islets were prein-
cubated in basal KRBB containing 2.8 mM glucose for 1 h. Islets
were then consecutively incubated at 2.8 and 16.7 mM glucose
for 1 h each. Medium was collected at the end of each incuba-
tion period. Insulin assays were performed in Eppendorf tubes
at 37 °C and 5% CO2.
For dynamic assessment of insulin secretion, we used a peri-
fusion system (Biorep) equipped with a peristaltic pump. Fifty
size-matched islets were placed in columns and perifused at a
flow rate of 100 l/min with KRBB at 37 °C. Perifusion started
with 2.8mMglucose for equilibration andmeasurement of basal
secretion and then exposed to different treatments. Medium
was collected to 96-well plates, and insulin was measured by
ELISA (Crystal Chem) and normalized to total islet DNA or
protein as indicated. DNA was isolated using DNeasy Blood
and Tissue kit (Qiagen).
-Cell LKB1 Controls Mitochondria and Insulin Secretion
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Measurement of Intracellular Free Ca2—Whole islets were
loaded with fura-2AM (Invitrogen) for 15min at 37 °C in KRBB
containing 119mmol/literNaCl, 4.7mmol/liter KCl, 2.5mmol/
literCaCl2, 1.2mmol/literMgSO4, 1.2mmol/literKH2PO4, and
25 mmol/liter NaHCO3. Fluorescence imaging was performed
using a CCD-based imaging system and MetaFluor software
(Universal Imaging), whereas islets were kept at 37 °C and con-
stantly perifused with KRBB containing 2.8 mM or 16.7 mM
glucose at a flow rate of 2.5 ml/min. Intracellular Ca2 was
expressed as the ratio of fluorescence intensity (at 535/30 nm)
after illumination at 340 and 380 nm. For each experiment we
used 8–20 islets (32). In some experiments Ca2 imaging was
performed using the non-ratiometric trappable fluorescent dye
fluo-2 and Nipkow spinning disc confocal microscopy as
described before (33).
Measurement of Intracellular Glutamate—Intracellular glu-
tamate was measured using Glutamate Assay Kit (Sigma,
MAK004) per the manufacturer’s instructions. We used 150
islets for each measurement. Calculated glutamate concentra-
tionwas normalized to total protein content (measured by BCA
kit, Pierce).
Mitochondrial Analysis—To measure mitochondrial mem-
brane potential we used TMRE (tetramethylrhodamine,
ethyl ester; Molecular Probes). Dissociated islet cells were
plated 2 days before the experiment on poly-D-lysine-coated
dishes. Cells were incubated for 1.5 h before imaging with
TMRE (10 nM) and MitoTracker Green (100 nM) loaded
together with the MDR inhibitor, verapamil (50 M), at 11
mM glucose. Analysis was performed using confocal imaging
after wash out of MitoTracker Green, and mitochondrial
membrane potential changes were calculated as previously
described (34).
NAD(P)H autofluorescence was measured using the same
imaging system and culture conditions described for calcium.
Autofluorescence derived from NADH was excited at 365 nm
and measured at 495 nm in dye-free islets. 6–15 whole islets
were used for each experiment. Fluorescence readings of each
islet were normalized to the first reading and averaged for each
mouse.
For ATP/ADP imaging, isolated islets were cultured for 48 h
with adenovirus (100 multiplicity of infection) expressing
Perceval (35, 36) in RPMI 1640 medium treated with 100
units/ml penicillin and streptomycin and 10% heat-inactivated
FBS. Islets were then placed in a custom-manufactured 36 °C
chamber (Digital Pixel) mounted on a Zeiss Axiovert micro-
scope coupled to a Nipkow spinning disk head. Islets were kept
at 36 °C and continuously perfused with bicarbonate buffer at
95% O2/CO2 (37). Results were normalized to the minimum
fluorescence (Fmin).
For real-timemeasurements of mitochondrial oxygen con-
sumption we used Seahorse XF analyzer (38). Islets (50/well)
were placed in 24-well islet plates with unbuffered DMEM
supplied with 1% FCS and 2.8 mM glucose at 37 °C without
CO2. Islets were then incubated at high glucose (16.7 mM)
followed by consecutive treatment with FCCP (carbonyl cya-
nide 4-(trifluoromethoxy) phenylhydrazone, 1 M) and rote-
none (5 M) plus antimycin (5 M). Oxygen consumption
rate (OCR) was calculated by the XF analyzer AKOS algo-
rithm and normalized to basal levels or to total protein con-
tent. Protein was extracted with radioimmune precipitation
lysis buffer, and total protein content was determined by
Pierce BCA kit (Thermo Scientific).
To measure mitochondrial DNA copy number, DNA was
isolated from fresh whole islets or from fixed sorted -cells by
standard phenol/chloroform extraction and ethanol precipita-
tion. Quantitative real-time PCR was used to evaluate the ratio
between cytochrome b (mitochondrial) and Aprt or L1 repeti-
tive element (nuclear) with the following primers: cytochrome
b, 5-GCAGTCATAGCCACAGCA TTT-3 and 5-AAGTG-
GAAAGCGAAGAATCG-3; Aprt, 5-GGGATATCTCGCC-
CCTCTT-3 and 5-CACTCGCCTGCGATGTAGT-3; L1,
5-GTTACAGAGACGGAGTTTGGAG-3 and 5-CGTTTG-
GATGCTGATTATGGG-3.
Transmission Electron Microscopy—Pancreas was fixed with
4% paraformaldehyde and 2.5% glutaraldehyde (Electron
Microscopy Sciences), post-fixed with 1% osmium tetroxide
(Sigma), and dehydrated with increasing concentrations of eth-
anol followed by propylene oxide (Sigma). For embedding we
used Agar 100 Resin (Agar Scientific). For imaging we used
80-nm sections stained with 5% uranyl acetate for 10 min fol-
lowed by 10min with lead citrate. Samples were visualized with
a transmission electron microscope (Technai 12, Phillips)
equippedwith aMegaView IICCDcamera. To assess structural
defects in mitochondria, we determined for each EM-imaged
mitochondrion whether it was swollen or had defective cristae.
Docked granules were counted up to 200 nm from the plasma
membrane and calculated as number of granules per mem-
brane length.
Western Blot—Protein was extracted from fresh islets by
radioimmune precipitation lysis buffer supplemented with the
protease and phosphatase inhibitors leupeptin, aprotonin, and
vanadate. Total protein was determined by Pierce BCA protein
assay kit (Thermo Scientific). Antibodies used were mouse
anti--actin 1:10,000 (Sigma) and rabbit anti cytochrome c
1:1000 (Cell Signaling).
Quantitative Real-time PCR—RNAwas isolated and purified
from fresh isletswithTRI reagent (Sigma) andRNeasymicro kit
(Qiagen). cDNA was synthesized using 200 ng of RNA by the
High-capacity cDNA Reverse Transcription kit (Applied Bio-
systems). For quantitative real-time PCR we used SYBR Green
mix (Quanta Biosciences) and the following primers: PGC1,
5-GAGCCGTGACCACTGACAA-3 and 5-TGGTTTGCT-
GCATGGTTCT-3; PGC1, 5-ATCGGGGTCCACCTT-
GAA-3 and 5-GGGTCACAGTTCTGGTTTGC-3; -actin,
5-CACAGCTTCTTTGCAGCTCCT-3 and 5-GTCATCC-
ATGGCGAACTGG-3. Reactionswere performed in triplicate
in 96-well plates using CFX96 real-time System (Bio-Rad).
Statistics—Statistical analyses were performed using un-
paired two-tailed Student’s t test. Data are presented as the
mean  S.E. (unless otherwise indicated). *, p  0.05; **, p 
0.01; ***, p 0.005; ns, p 0.05.
Results
LKB1 Deficiency in  Cells Leads to Persistent Enhancement
of Glucose-stimulated Insulin Secretion—We and others have
previously shown that GSIS is enhanced after Cre-mediated
-Cell LKB1 Controls Mitochondria and Insulin Secretion
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deletion of LKB1 in  cells in vivo (23–25, 30). These observa-
tions were mostly obtained a short time after deletion of LKB1.
To test if hyperfunctionality of  cells in LKB mice declines
with age, as seen in human type 2 diabetes and in some mouse
models exhibiting enhanced insulin secretion (39), we mea-
sured glucose tolerance and serum insulin levels in LKB mice
up to 16 months after deletion. Injected glucose was cleared
faster inmutantmice (Fig. 1A) along with greater insulin secre-
tion (Fig. 1B). Thus deletion of LKB1 in  cells causes a persis-
tent enhancement of  cell function.
Multiple mechanisms have been proposed to underlie
increased insulin secretion in LKBmice (23–25).We assessed
 cell mass usingmorphometric analysis but found only a small
increase in LKB mice compared with controls (37% or less,
depending on calculation method), which cannot explain the
dramatic enhancement of insulin secretion (Fig. 1C). More-
over, total pancreatic insulin content was identical inLKB and
control mice in both the fasting and fed states (Fig. 1D), further
suggesting that increased insulin secretion is not due to modu-
lation of insulin content.
To characterize insulin secretion in greater detail, we ana-
lyzed GSIS in islets isolated from LKB and control mice and
normalized the measurements to DNA content. Similarly to
our in vivomeasurements in perfused pancreata (23), perifused
LKB islets secreted normal levels of insulin in low glucose but
showed greatly enhanced insulin secretion upon a shift to high
glucose (Fig. 1E). The temporal pattern of secretion was normal,
with more insulin released in both the first and second phases.
When KCl was added to obtain maximal secretion, LKB islets
secreted 2-fold more insulin than controls. These results rule out
mechanisms of secretion that may operate in vivo only, for exam-
ple more rapid or efficient secretion to blood due to altered cell
FIGURE1. Increased insulin secretiondespitenormal insulin content and cellmassafter LKB1 loss.A, glucose tolerance test in oldLKBmice.Micewere
injectedwith tamoxifen at 1month of age, and assays were performed 16months later. n	 4 or 5 per genotype. p value0.05 by repeatedmeasures analysis
of variance. B, plasma insulin levels in old LKBmice, 15min after glucose injection. Error bars represent S.D. Mice were injected with tamoxifen at 1month of
age, and assaywas performed 1 year later. n	 3 per genotype. C, cell mass. Graphs represent the percentage of pancreas tissue area stained for insulin (left),
the fraction of insulin-stained tissuemultiplied by pancreas weight (total  cell mass in mg; center), and total  cell mass per body weight (right). Mice were 4
months old, 3months after tamoxifen injection. n	 3mice per group.D, insulin content in pancreata from fed and fasted lox/lox littermate controls andLKB
mice. Insulin content is presented relative to pancreas weight.LKBmice do not differ in their pancreatic insulin content in either fed or fasted states. n	 4–7
mice per group. E, dynamic insulin secretion assay. Data represent themean of data from 5mice per group at age of 6–8months. For each sample, measured
insulin was normalized to total DNA. *, p 0.05; **, p 0.01; ***, p 0.005; ns, p 0.05.
-Cell LKB1 Controls Mitochondria and Insulin Secretion
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polarity. Rather, they demonstrate that persistent enhanced secre-
tion inLKBmice is cell autonomous andpoint to amechanism
distal to plasmamembrane depolarization.
KATP and Calcium Channels Are Required but Not Sufficient
for Enhanced Insulin Secretion in LKB Mice—To clarify how
LKB islets secrete more insulin in response to glucose, we
perturbed steps in the triggering pathway for insulin secretion.
Treatment with diazoxide, a KATP channel opener, completely
abolished glucose-stimulated secretion in perifusedLKB islets
(Fig. 2A). This suggested that closure of KATP channels and
membrane depolarization are essential for enhanced secretion
in the mutants. However, when channels were forced to open
with diazoxide and KCl was added, LKB islets secreted more
insulin than controls, consistent with the findings in Fig. 1E.
FIGURE 2. Insulin secretion in LKB1-deficient cells isKATP-dependent. A, insulin levels during an islet perifusion assay. Switchingmedium from2.8 to 16.7
mM glucose (G16.7) causes higher secretion in LKB1-deficient islets. Diazoxide (Dia) (100M) abolishes secretion in both control andmutant islets, and further
additionof 30mMKCl triggers a secondpeakof secretion.Data represent themeanof 2groupsof islets taken fromdifferentmice at ageof 2.5months.B, insulin
secretion during islet perifusion with glyburide. Glyburide (1 M) triggers dramatically more insulin secretion from LKB1-deficient islets in either low or high
glucose. Data representmean of data from three (control) and five (LKB1-deficient) mice. C, serum insulin and glucose levels after administration of nifedipine
(Nif) to lox/lox and LKB1-deficient mice after an overnight fast. Nifedipine (10 mg/kg in 5% DMSO) was injected at time 0. Glucose was injected at 45 min.
Glucose was measured at 0, 45, and 60min, and insulin was measured at 60min. Mice were 3–12months old. n	 6–9mice per group. D, glucose-stimulated
insulin secretion fromperifused islets treatedwith nifedipine.Dashed lines, nifedipinewas added before high glucose. Solid lines, nifedipinewas added 15min
after the addition of highglucose. In both cases no significant differencewas observedbetween lox/lox andLKB islets in thepresence of nifedipine. Statistical
significance is shown for the experimentwhere nifedipinewas added after high glucose. E, left, representative plots of calcium influx after glucose stimulation
ofwild type andLKB islets. Isletswereperifusedwith KRBbuffer containing2.8 or 16.7mMglucoseor 30mMKCl as indicated. Intracellular calcium is calculated
by the ratio of emission at 340- and 380-nmwavelengths using Fura-2 dye. Each plot represents the average ratio of 8–20 islets taken from onemouse. Right,
calculation of 6 parameters of calcium response in lox/lox andLKB islets, based on the calciumplots. Micewere 6months old, n	 3 per genotype. *, p 0.05;
**, p 0.01; ***, p 0.005; ns, p 0.05.
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Thus in the face of a similar degree of membrane depolariza-
tion, LKB islets secrete more insulin, indicating enhancement
of secretion at a distal step of the pathway (Fig. 2A). Further-
more, treatment with glyburide (forcing the closure of KATP
channels) led to higher insulin secretion from cultured LKB
islets both at basal (2.8 mM) and stimulating (16.7 mM) glucose
concentrations (Fig. 2B). In addition, in vivo administration of a
high dose of glyburide boosted plasma insulin levels to a higher
degree inLKBmice comparedwith controls (data not shown).
This further indicates a component boostingGSIS downstream
to membrane depolarization.
Wenext treatedmicewith nifedipine, an inhibitor of voltage-
gated calcium channels. Under these conditions, serum insulin
levels after glucose injection were dramatically and equally
reduced in LKB and control mice (Fig. 2C), and blood glucose
levels rose to equally high levels in mutants and controls. Sim-
ilar results were obtained when we treated perifused islets with
nifedipine and measured glucose-stimulated insulin secretion.
As shown in Fig. 2D, nifedipine dramatically reduced insulin
secretion in both LKB1-deficient and wild type islets. These
results indicate that L-type calcium channels are required for
insulin secretion in LKB islets.
To better understand calcium dynamics in LKB islets, we
measured intracellular calcium flux in isolated islets exposed to
different glucose levels. We incubated islets at different glucose
concentrations and imaged them in the presence of Fura-2AM, a
sensitive indicator for intracellular free calcium ions. Surprisingly,
LKB islets had abnormally high levels of Ca2 at low glucose
(presumably not reaching the threshold needed for a measurable
increase in insulin secretion). More importantly, LKB1-deficient
islets largely failed to enhance calcium in response to high glucose.
Calcium levels in LKB islets did rise upon treatment with KCl,
suggesting that forced membrane depolarization does mobilize
calcium inmutant cells (Fig. 2E). Further analysis using the fluo-2
dyeconfirmed that theamplitudeof the responsewasadecrease in
LKB1-deficient cells (not shown) and demonstrated that the frac-
tion of responding  cells was decreased in LKB islets (lox/lox,
66.9 6.1% cells responding;LKB, 28.7 6.1% responding; p
0.01). Thus, LKB islets have a defect in glucose-stimulated cal-
cium entry, likely at a step upstream tomembrane depolarization.
Nonetheless, and remarkably, this defect does not interfere with
enhanced GSIS.
Altered Responses to Succinate and Leucine in LKB Islets—
Glucose triggers calcium entry and insulin secretion via its oxi-
dative phosphorylation in themitochondria and the generation
of ATP, leading to closure of KATP channels. We hypothesized
that the defect in glucose-induced calciumdynamics reflected a
defect inmitochondrialmetabolism. To test this idea, we exam-
ined insulin secretion from LKB islets in response to mito-
chondrial fuels. Perifusion of islets with glutamine (which can
enter the TCA cycle through activity of glutamate dehydroge-
nase) did not increase insulin secretion at low glucose levels in
both LKB and control islets. However, glutamine combined
with leucine, an activator of glutamate dehydrogenase (40), did
trigger insulin secretion at low glucose (Fig. 3A), and this
response was stronger in LKB islets compared with controls.
Surprisingly, control experiments where leucine was added
alone revealed a similar increase in insulin secretion. The
response to leucine alone was higher in LKB than in control
islets, and themagnitude of the effect was similar to that seen in
response to glucose (Fig. 3B).
We then treated islets with another classic mitochondrial
substrate, monomethyl succinate (added to islets together with
low levels of -ketoisocaproate (41)). Strikingly, succinate did
induce insulin secretion in control islets but failed to do so in
LKB islets.
These results support the idea that LKB islets have a defect
in mitochondrial-induced calcium entry and insulin secretion.
In addition, they suggest that LKB islets are more sensitive to
a mitochondrial-independent secretory stimulation by leucine.
Lkb1 Is Essential for Normal Oxidative Mitochondrial
Function—The failure of succinate to increase insulin secretion
and the defect in glucose-induced calcium mobilization
prompted us to examinemitochondrial function ofLKB islets.
We first analyzed mitochondrial membrane potential in cul-
tured dissociated islet cells from LKB and control mice using
the mitochondrial membrane potential-sensitive dye TMRE.
Measuring fluorescence intensity of TMRE by confocal imag-
ing showed reduced TMRE in LKB islet cells (2 months post
deletion of LKB1). Importantly, co-stainingwith themitochon-
drial membrane potential-non-sensitive mitochondrial mass
dye, MitoTracker Green, showed no difference in LKB islet
cells (Fig. 4A). Using a modified version of the Nernst equation
(34), we translated the reduction in TMRE fluorescence inten-
FIGURE 3. Effects of glutamine, leucine, and succinate on insulin secretion. A, islet perifusion assaywith glutamine (Gln) or glutamine leucine (GlnLeu)
at low glucose. Each plot represents the mean of two different mice. Mice are 6 months old. Right, mean of area under the curve (AUC) calculated for the
perifusion plots. B, insulin secretion in response to glucose (16.7 mM), leucine (10 mM, in the presence of 3 mM glucose), and methyl succinate (10 mM) plus
-ketoisocaproate (KIC; 2mM) in lox/lox andLKB islets using static incubation.Micewere 4months old. Data represent themeanof three or four independent
experiments. *, p 0.05.
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sity to 
 3 mV in LKB islets cells. Thus, deletion of LKB1
causes relative depolarization of  cell mitochondria.
Measurements of NAD(P)H also indicated a mitochondrial
defect in LKB islets. NAD(P)H levels were dramatically
increased in control islets perifused with high glucose and
returned to baseline upon transfer to low glucose. By contrast,
the NAD(P)H response to glucose was significantly blunted in
LKB islets (5 months post LKB1 deletion), indicating a defect
in mitochondrial glucose metabolism (Fig. 4B). Furthermore,
by using the ATP/ADP ratio probe, Perceval (36), we showed
that the glucose-induced rise in ATP/ADP ratio (which is the
direct mediator of KATP channel closure, calcium entry, and
insulin secretion) was prominent in controls but reduced in
mutant islets (Fig. 4C). The effect was evident both by a reduced
amplitude of response (Fig. 4D) and by a smaller fraction of cells
that responded to stimulus (Fig. 4E).
We also assessed the rate of oxygen consumption in LKB
islets using the Seahorse XF analyzer. OCR was measured in
low glucose, then in response to high glucose, and then after
adding the mitochondrial uncoupler FCCP to force maximal
oxygen consumption. Although basal OCR was similar in con-
trol and LKB islets (Fig. 4F), oxygen consumption at high glu-
cose was lower inLKB islets (Fig. 4G). Even forced uncoupling
using FCCP elicited reduced OCR in LKB islets compared
with controls. Blocking the respiratory chainwith rotenone and
antimycin resulted in complete abolishment of oxygen con-
FIGURE 4. Lkb1 deletion in  cells disrupts mitochondrial function. A, quantification of fluorescence intensity of TMRE (left) and MitoTracker Green (MTG,
right) in islet cells from lox/lox andLKBmice.Micewere 3months of age, 2months post-tamoxifen injection. Thegraphpresents themeanof fivemice in each
genotype. 20–30 fields were imaged and averaged per mouse. The difference in fluorescence intensity of TMRE is translated to 
 3 mV between lox/lox and
LKB cells.B, NAD(P)Hproduction in response to 16.7mMglucose. Theplots represent themeanofNAD(P)H-derived fluorescence intensity inwhole islets from
lox/lox (n	 4) andLKB (n	 4)micemeasured byUV autofluorescence. Isletswere perifusedwith 2.8mMglucose for 12min thenwith 16.7mM for 15min and
back to 2.8 mM. Mice were 6 months old, 5 months post-tamoxifen injection. Right, mean of area under the curve (AUC) of the NAD(P)H plots. *, p 0.05. C,
cytosolic ATP/ADP ratio changes in islets in response to glucose. Glucose was changed during the experiment from 3 mM (G3) to 11 mM (G11). Note the
significantly impaired response in LKB1 islets. AU, arbitrary units. Data are from three wild type and three LKB mice. D, amplitude of responsiveness
presented in C. E, ATP/ADP ratio presented as % of islets responsive to glucose. *, p 0.05. F, basal OCRmeasured by Seahorse XF24 analyzer in the presence
of 2.8mMglucose.ns,p 0.05.G, OCRmeasuredover time. Data are presented as -fold induction frombasal OCRpresented in F. Eachplot represents themean
of 7 wells with 50 islets each fromwild type (n	 3) or LKB (n	 4) mice. Mice were 2.5 months old. Compounds injected at indicated times were glucose (20
mM), FCCP (1M), and rotenoneplus antimycinA (R/A, 5Meach).H, OCR in thepresenceof glutamine and leucine (GlnLeu). Protocol is as described inG. Each
plot represents the mean of 6 or 7 wells with 50 islets from wild type (n 	 5) or LKB (n 	 4) mice. Mice were 6 month old. The assay were performed on
Pdx1-CreERTM;LKB1 lox/lox mice, except for ATP measurements (C–E) that were performed on Ins1-Cre;LKB1lox/lox mice aged 10 weeks.
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sumption in both control and LKB islets, excluding non-mi-
tochondrial oxygen consumption in either genotype. Lastly, we
tested the effect of leucine and glutamine on OCR. The
response of mutant islets to these amino acids was similar or
reduced compared with wild type islets (Fig. 4H), supporting
the idea that they boost insulin secretion in Lkb1-deficient
islets via a mitochondria-independent mechanism. Together,
these studies reveal a dramatic functional defect in the mito-
chondria of Lkb1-deficient  cells.
Deletion of Lkb1 Leads to Mitochondrial Destruction—To
understand the basis for the functional defect in mitochondria
of LKB  cells, we examined mitochondrial structure at high
resolution using transmission electron microscopy. Islets of
control islets presented with a typical pattern of mitochondria,
including the fine structure of cristae (Fig. 5A). Islets of LKB
mice, examined 3–10months after deletion of LKB1, revealed a
strikingly different pattern of mitochondria. Mitochondria in
mutant  cells were swollen and absent of cristae. The effect
was specific to  cells, as adjacent  cells in the same sections
had the normal appearance of mitochondria (Fig. 5B). The lat-
ter observation also rules out artifacts related to fixation and
processing of tissue. The mitochondrial defect was found in
60% of  cells in LKB islets (n	 6mice, 15–20 cells examined
per mouse) compared with 12% of mitochondria that had
such appearance in wild type islets (Fig. 5C). In affected  cells,
allmitochondriawere apparently disrupted. This suggests a cell
autonomous, all or none effect, occurring in the LKB1-deleted
 cells and sparing cells that have escaped cre-mediated dele-
tion.We have not observed other ultra-structural alterations in
LKB islets beyond the previously reported distended endo-
plasmic reticulum (42). In particular, we tested whether LKB1-
deficient islets had more insulin granules docked at the plasma
membrane (up to 200 nm from the membrane) as a potential
indication for enhancement in distal release but found no dif-
ference between wild type and mutant islets (data not shown).
Assessment of the mitochondrial protein cytochrome c by
Western blotting revealed a moderate decrease in LKB islets
(Fig. 5D). Quantitative PCR revealed a trend for a reduction in
mitochondrial DNA (ratio of cytochrome bDNA toAprtDNA)
that did not reach statistical significance, possibly due to the
presence of non- cells as well as non-recombined cells in the
islet preparations. Indeed, whenmitochondrial DNAwas mea-
sured in sorted cells, we observed an30% reduction inmito-
chondrial/nuclear DNA ratio in  cells isolated from LKB
mice (Fig. 5E). Consistent with the moderate decrease in mito-
chondrial protein and DNA seen in LKB islets, there was no
FIGURE 5. LKB1 is essential for mitochondrial integrity. A, representative transmission electronmicrographs of pancreatic sections showingmitochondria
(arrows) in cells in lox/lox andLKBmice. Mice were 10months old, 9months after tamoxifen injection. B, a section from an islet of an LKB1-deficientmouse
showing intact mitochondria in two -cells. Arrows point to mitochondria. C, quantification of the percentage of  cells with defective mitochondria (swollen
mitochondria or lack of cristae) as determined by analysis of EM images. *, p 0.05.D, Western blot of cytochrome c protein normalized to actin on islets from
twowild typemice and two LKBmice. Mice were 5months old. E, mitochondrial DNA copy number measured by the ratio betweenmitochondrial DNA and
nuclear DNA from lox/lox and LKB whole islets (left) or sorted  cells (right) using qPCR. For whole islets, data represent the mean of DNA ratio (cytochrome
b/Aprt) from 4–5mice at 4 and 10months of age. For sorted  cells, data represent the ratio of DNA (cytochrome b/L1) pooled from 4mice per genotype at 1
year of age. F, PGC1andPGC1mRNA levels quantifiedbyRT-PCR fromwild typeandLKB islets normalized toactin.Data represent themeanS.E. of 4mice
at age of 4.5 months. ***, p 0.005.
-Cell LKB1 Controls Mitochondria and Insulin Secretion
AUGUST 21, 2015•VOLUME 290•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 20941
 at Im
perial College London on O
ctober 7, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
difference in the intensity of fluorescence when control and
LKB islets were treated with the mitochondrial mass marker
MitoTracker Green (Fig. 4A).
Finally, we sought to identify the molecular basis for degen-
eration of mitochondria in LKB1-deficient  cells. PGC1 and
PGC1 are central nuclear transcriptional regulators of mito-
chondrial biogenesis (43, 44) that were shown in other systems
to be regulated at the mRNA level by phosphorylated AMPK, a
central target of LKB1 (45, 46). Quantitative PCR analysis
revealed a 2-fold reduction of PGC1 and PGC1 mRNA in
LKB islets compared with controls (Fig. 5F), potentially
explaining the mitochondrial defect via a LKB1-AMPK-PGC1
axis.
Evidence for Cell Autonomous Effects of LKB1 on Insulin
Secretion and Energy Metabolism—The deletion of LKB1 in 
cells in vivo is incomplete, as in most tamoxifen-inducible
mouse systems. Therefore, the phenotypes analyzed here could
in principle reflect either a cell autonomous, direct effect of
LKB1 deletion in  cells or, alternatively, a compensatory effect
in wild type  cells.We showed before that LKB1 deletion leads
to improved glucose tolerance in vivo as early as 1 week after
tamoxifen injection (23), strongly suggesting that the underly-
ing mechanism is a direct enhancement of insulin secretion
from LKB1-deficient  cells. In addition, a recent paper has
documented enhanced secretion in min6 cells with LKB1
knockdown (47), further supporting this conclusion. To exam-
ine whether the energymetabolism phenotype (defective mito-
chondrial function) also acts in a cell autonomous manner, we
reintroduced wild type LKB1 via adenoviral infection to cul-
tured LKB1-deficient islets.Within 48 h of infection, LKB1 lev-
els in mutant islets were restored (Fig. 6A), and both calcium
influx and ATP levels were restored to near-normal levels
(Fig. 6, B and C). These results indicate that the defects in
energymetabolism in LKB1-deficient islets are a direct effect of
FIGURE 6. In vitro rescue of LKB1-deficient cells. A, LKB1mRNA levels measured by qRT-PCR in culturedwild type and LKB islets, 48 h after infection with
adenoviruses encodingwild typeLKB1.n	3mice/condition. Cellswere infectedat themultiplicity of infection indicated. *,p0.05; **,p0.01; ***,p0.005.
B, rescueof glucose-stimulated calcium influx in LKB1-deficient islets. Both theamplitude (center) and the fractionof responding cells (right) returned tonormal
upon LKB1 re-expression. n	 3 mice per genotype, 9–12 islets per genotype. AU, arbitrary units. C, rescue of glucose-stimulated [ATP/ADP]cyt rise in LKB1-
deficient islets. Both the amplitude (center) and the fraction of responding islets (right) are improved upon LKB1 re-expression. n	 5mice per genotype, 9–15
islets per genotype. *, p 0.05; **, p 0.01.
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LKB1 loss in  cells rather than an indirect compensatory
mechanism.
Discussion
We show here two opposing effects of LKB1 deficiency in
pancreatic  cells. The absence of LKB1 causes dramatic func-
tional and structural defects in the mitochondria of  cells.
On the other hand, glucose-stimulated insulin secretion is
enhanced in LKB1-deficient cells, in vivo and in isolated islets,
and persists for at least 16 months after deletion of the gene.
Moreover, mice with LKB1-deficient  cells were shown to
resist high fat diet-induced glucose intolerance (25). Our find-
ings suggest that LKB1 deficiency stimulates a robust ampli-
fying pathway, which overrides the defects in the classical
triggering pathway of insulin secretion relying on oxidative
metabolism of glucose to ATP.
Regulation of Glucose-stimulated Insulin Secretion by
LKB1—LKB1 deficiency causes a dramatic enhancement of
GSIS (this work and Refs. 23, 24, and 25), but this net effect
reflects the integration of multiple phenotypes acting in oppos-
ing directions. Previous studies showed that two LKB1 phos-
phorylation targets, SIK2 and SAD-A, positively regulate insu-
lin secretion, such that in their absence there are secretion
defects (26, 27). As for AMPK, its effect on GSIS has remained
controversial (48–50), perhaps because its own downstream
effectors act in opposing directions on the secretorymachinery,
potentially in a context-dependentmanner. In the presentwork
we report that LKB1 is essential formitochondrial function in
cells (see below). This adds a major hurdle to GSIS in LKB1-
deficient  cells. Indeed, mitochondrial oxidation of glucose
and the TCA cycle fuel succinate is defective, rendering the
classic triggering pathway inactive in LKB1-deficient  cells. In
light of these defects, the dramatic enhancement of GSIS in
mutantsmust involve powerful pro-secretionmechanisms that
override the multiple intrinsic defects.
Our work provides molecular evidence on how a lack of
LKB1 in  cells improves GSIS. First, the improvement cannot
be merely a consequence of increased  cell mass or pancreatic
insulin content. We found that, in tamoxifen-deleted strains,
insulin content in LKB pancreata was not significantly
increased, and  cell mass was only moderately increased to a
degree that cannot explain the robust increase in secretion (we
note, however, that increases in  cell mass may play a more
significant role in enhanced in vivoGSIS in the in utero-deleted
models (24, 30). The observation of increasedGSIS in perifused
islets (with normalization to DNA content in the sample) fur-
ther suggests that insulin secretion is enhanced in a cell-auton-
omousmanner. Second, reversed cell polarity is unlikely to be
the cause for enhanced GSIS. Although altered polarity of
LKB cells could theoretically promote insulin secretion in
response to glucose (23), the fact that LKB1-deficient islets
secrete more insulin in vitro, where blood vessels and the cir-
culation play no role, argues against this possibility.
Even though the classic triggering pathway (51) is defective
in LKB1-deficient  cells, some level of calcium entry via volt-
age-gated calcium channels is essential for insulin secretion in
these cells, as prevention of membrane depolarization or inhi-
bition of calcium channels eliminated secretion in themutants.
These findings point to a distal component as the key determi-
nant of enhanced GSIS in LKB1 mutants. Although the exact
molecular mechanism remains elusive, an important hint
might be the responsiveness of LKB1-deficient  cells to leu-
cine. Leucine is normally considered a secretagogue via its acti-
vation of glutamate dehydrogenase in the mitochondria, sup-
plying -ketoglutarate to the TCA cycle (40, 52). However, this
is unlikely the mechanism of action in LKB1-deficient  cells
that contain dysfunctionalmitochondria and do not respond to
succinate. Alternatively, leucine can also be metabolized by
transamination. This may increase the concentration of gluta-
mate in  cells, which has been shown recently to boost insulin
secretion via intracellular activity on the exocytosis machinery
(53–55), although this has been controversial (56). Interest-
ingly, our transcriptome analysis of LKB1-deficient  cells has
revealed major alternations in pathways related to glutamine
and glutamate synthesis and processing (30). Specifically, cyto-
solic aminotransferases (Bcat1 and Tat) were significantly up-
regulated (by 4.5- and 1.7-fold, respectively) in LKB1-deficient
islets. We thus speculate that increased levels of intracellular
glutamate in LKB1-deficient  cells primes for more effective
glucose-stimulated insulin secretion, requiring less calcium
to trigger release. Consistent with this idea, we measured
increased glutamate levels in LKB1-deficient islet cells (lox/lox,
0.02 0.002 nmol glutamate/g of protein;LKB, 0.03 0.002
nmol of glutamate/g of protein; p  0.05). Importantly, our
previous study (30) also demonstrated a substantial up-regula-
tion of genes involved in glutamate signaling in LKB1 islets
and increased responsiveness to exogenously applied glutamate
receptor agonists. It is, therefore, tempting to speculate that an
action of intracellular glutamate on secretory granules them-
selves (57) or enhanced release of glutamate into the extracel-
lular space and agonism at cell surface glutamate receptorsmay
contribute to enhanced insulin secretion in LKB1 null  cells.
A very recent paper from Screaton and co-workers (47) also
examined cell function in the absence of LKB1. Their findings
are in general agreement with ours, in that GSIS is enhanced in
mutant  cells despite a mitochondrial defect. However, their
proposedmechanism involves glutamine to citrate metabolism
as well as increased activity of acetyl-CoA carboxylase 1
(ACC1). In addition, Fu et al. (47) have described increased
insulin granule docking in LKB1 mutant  cells, which was not
observed in the current study.Morework is needed to test these
ideas and to identify the precise molecular mechanisms that
enhance GSIS in LKB1-deficient  cells, including the relevant
LKB1 phosphorylation target(s). Regardless, our findings high-
light the relative importance of distal components in the insulin
secretion pathway (amplifying signals) compared with the clas-
sic triggering pathway.
These findings may have implications beyond the under-
standing of LKB1 biology. Enhanced glucose-stimulated insulin
secretion is a common compensatory mechanism in  cells
under an increased workload (e.g. insulin resistance), but com-
pensation often turns into decompensation, resulting in the
development of type 2 diabetes (58). This biphasic behavior of
cells is not fully understood but appears to be a universal phe-
nomenon seen not only in type 2 diabetes but also in congenital
hyperinsulinism (59–61) and in different rodent models such
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as leptin receptor deficient mice (db/db), (62),  cell-specific
deletion of TSC2 inmice (39), and Psammomys obesus exposed
to a high calorie diet (63). LKB1-deficient cells are remarkable
not only due to the enhancement of GSIS in the face of degen-
erated mitochondria (and virtually absent triggering pathway
for secretion) but are also due to the persistence of the pheno-
type. Even 16 months after LKB1 deletion, LKB mice showed
greater insulin secretion and consequently improved glucose
tolerance, with no evidence for decompensation. This shows
that  cells, even in the face of mitochondrial dysfunction and
additional defects in the secretion machinery, can still be
manipulated to boost insulin secretion over long periods of
time. A drug that mimics the pro-secretion activity of LKB1
deficiency can theoretically cause a long term improvement of
 cell function in type 2 diabetes patients.
Regulation of Mitochondrial Structure and Function by
LKB1—We found that LKB1 deficiency in  cells leads to mito-
chondrial degeneration, as illustrated by electron microscopy.
This is accompanied by functional defects in oxidative metab-
olism as well as in downstream signaling such as calcium entry.
Thus LKB1 is essential for the maintenance of mitochondria in
adult  cells. We propose that the underlying mechanism is
control of mitochondrial biogenesis via PGC1, a known target
of phospho-AMPK (45, 46) and a key regulator ofmitochondria
(43, 44). In support of this hypothesis, the levels of PGC1 and
PGC1 were significantly down-regulated in LKB1-deficient 
cells. We note, however, that ectopic expression of PGC1 was
shown before to cause islet failure and impaired insulin secre-
tion (64). The different phenotype in our study likely results
from the pleiotropic effect of LKB1in  cells. Alternatively,
LKB1-deficient cells may have defects in mTOR-controlled
mitophagy (65, 66), leading to the accumulation of defective
mitochondria. Previous studies have shown that LKB1 is an
important regulator of mitochondrial metabolism (although
ultrastructural defects as in our study were not reported), but
the effect was proposed to be unique to hematopoietic stem
cells (20–22). Our work suggests that LKB1 is universally
important for mitochondrial homeostasis. Considering the
established role of LKB1 as a tumor suppressor, this notion
provides a newmechanism for aerobic glycolysis in cancer (the
Warburg effect). Interestingly, although current thinking
describes aerobic glycolysis as a normal feature of rapidly pro-
liferating cells (67), Otto Warburg himself was convinced that
cancer cells use aerobic glycolysis due to defects in their mito-
chondria (68). To the best of our knowledge LKB1 is the only
tumor suppressor whose absence indeed damages the mito-
chondria.We found no evidence for enhancement of glycolysis
in LKB1-deficient cells, although in other systems it was dem-
onstrated that LKB1 loss does increase glucose uptake and gly-
colysis via the activity of HIF1, a master regulator of glycolytic
gene expression (69, 70).
In summary, we show here that LKB1 is essential for the
maintenance of mitochondria in adult pancreatic  cells, a
function that is likely exerted by LKB1 in multiple cell types.
Although the mitochondrial defect in LKB1-deficient  cells
acts to impair fuel-stimulated insulin secretion, surprisingly,
the net effect of LKB1 deficiency in  cells is a persistent
improvement of glucose-stimulated insulin secretion and con-
sequently glucose tolerance, likely via effects on distal steps in
the secretionmachinery. Unraveling themolecular mechanism
underlying increased insulin secretion in LKB1-deficient cells
may open new therapeutic approaches for type 2 diabetes.
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